Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19

BMJ. 2020 Oct 16:371:m3869. doi: 10.1136/bmj.m3869.

Huseyin Naci¹, Aaron S Kesselheim², John-Arne Røttingen^{3

4}, Georgia Salanti⁵, Per O Vandvik⁶, Andrea Cipriani^{7

8}

¹ Department of Health Policy, London School of Economics and Political Science, London, UK h.naci@lse.ac.uk.
² Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
³ Research Council of Norway, Oslo, Norway.
⁴ Blavatnik School of Government, University of Oxford, Oxford, UK.
⁵ Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
⁶ Department of Health Management and Health Economics, University of Oslo, Oslo, Norway.
⁷ Department of Psychiatry, University of Oxford, Oxford, UK.
⁸ Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK.

No abstract available

Publication types